0.90
0.90 (0%)
As of Feb 14, 2025
Xortx Therapeutics Inc. [XRTX]
Source:
Company Overview
XORTX Therapeutics is a late clinical-stage biotechnology company focused on identifying, developing and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as ADPKD and type 2 diabetic nephropathy, as well as AKI associate with respiratory virus infection.
| Country | United States |
| Headquarters | vancouver |
| Phone Number | 403-607-2621 |
| Industry | |
| CEO | Allen Davidoff |
| Website | www.xortx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | |
| Net Income | |
| Net Cash |
Profit Ratios
| Gross Margin | |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | |
| Profit as % of Stockholder Equity |
Management Effectiveness
| Return on Equity | |
| Return on Assets | |
| Turnover Ratio | |
| EBITA |
Balance Sheet and Cash Flow Measures
| Total Assets | |
| Total Liabilities | |
| Operating Cash Flow | |
| Investing Cash Flow | |
| Financing Cash Flow |
